EVis Bioscience develops innovative gene delivery systems for targeted and personalized medicine. This includes extracellular vesicles, synthetic lipid nanoparticles, and their hybrids.
Based in Zürich, the ETH spin-off aims to provide an alternative approach to viral vectors for treating genetic disorders.
Further, the company offers sub-licenses of its vehicle to Pharma Companies and/or Research Labs that intend to develop gene-based formulations for specific medical applications.
The BSL-Class 2 laboratory is equipped with
• Microfluidics
• Dynamic Light Scattering
• Nanoparticle Tracking Analysis
• Nano Flow Cytometry
• Cell culture facilities
• Advanced microscopy techniques and animal facilities through scientific collaboration with the University of Zürich
For more information, please visit our website: www.evis-bioscience.com
Company Details
- Employees
- 2
- Founded
- -
- Address
- Wagistrasse 18, Schlieren,zurich 8952,switzerland
- Industry
- Nanotechnology Research
- NAICS
-
Research and Development in Nanotechnology
- HQ
- Schlieren, Zurich
Evis Bioscience Ag Questions
Evis Bioscience Ag's LinkedIn profile is https://ch.linkedin.com/company/evisbioscience
Evis Bioscience Ag has
2 employees.
View email and phone details for 2
employees at Evis Bioscience Ag.
Evis Bioscience Ag's industry is
Nanotechnology Research
Evis Bioscience Ag's top competitors are
Femtog,
2hs Ag,
Procavea Biotech,
Apersys Ag,
Cellx Biosolutions,
Avientus,
Anevo,
Byldr,
Myria Biosciences Ag,
Calspak.
Evis Bioscience Ag's categories are Nanotechnology Research
Evis Bioscience Ag's founding year is 2024
